Billionaire-Backed Cancer Researcher Claire Mazumdar Finds Entrepreneurial Niche [Forbes]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Forbes
But the young cancer researcher has quietly taken up the challenge. Mazumdar, 35, is the CEO of Boston-based , a Biocon spinoff that's developing a new class of cancer drugs. The most promising one in Bicara's pipeline is a dual-action antibody called BCA101 with the potential to treat head and neck cancers. The sixth most common type of cancers worldwide, they are associated with tobacco consumption, alcohol abuse, and human papillomavirus (HPV) infection. Mazumdar hopes the drug under development, which targets the epidermal growth factor receptor (EGFR) on cancerous tumors to contain them while simultaneously improving the immune system's response, can be a gamechanger for patients with a poor prognosis even after chemotherapy. “That would be a dream and an aspiration come true,” says Mazumdar in a video interview. Mazumdar's Bicara Therapeutics is developing BCA101, a dual-action antibody with the potential to treat head and neck cancers. So far, several marquee investors ha
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- [Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]Latest
- Here's Why Merck (MRK) Stock Has Outperformed Industry YTD [Yahoo! Finance]Yahoo! Finance
- Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates [Yahoo! Finance]Yahoo! Finance
- Global Veterinary Eye Care Market Size, Share & Trends Analysis Report 2024-2030: Collaborative Efforts Advance Early Detection, Laser Therapy Gains Popularity, New Technologies Elevate Care [Yahoo! Finance]Yahoo! Finance
- Cramer says these 10 stocks helped the Dow briefly crack 40,000 [CNBC]CNBC
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 5/15/24 - Form 424B5
- 5/15/24 - Form POSASR
- 5/6/24 - Form 144
- MRK's page on the SEC website